Subgroups of patients with BRAF-mutated melanoma treated with BRAF and MEK inhibitors are associated with distinct survival outcomes, based on clinical characteristics (LDH levels, ECOG PS, presence of liver metastasis and tumour size [SLD]).11,12 When patients in the pooled treatment cohorts were sorted into these prognostic subgroups, we found greater median tumour reduction in subgroups associated with good prognosis and lesser median tumour reduction in subgroups associated with poor prognosis (Table 2). The gene discussed is BRAF; the disease is neoplasm.